Abstract
Recently a study with a new hepatitis B vaccine consisting of hepatitis B surface antigen formulated with the adjuvants 3-deacetylated monophosphoryl lipid A (MPL) and Quillaja saponaria (QS21) was exceptionally successfull leading to a hightitered longlasting antibody response in sixteen of twenty patients (Bienzle et al., Hepatology 2003;38: 811–819). In the investigation presented here we analysed cellular immune responses of the successfully vaccinated participants of this study.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call